MML Investors Services LLC decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 186,875 shares of the biopharmaceutical company's stock after selling 3,814 shares during the quarter. MML Investors Services LLC's holdings in Gilead Sciences were worth $17,262,000 at the end of the most recent reporting period.
Several other large investors also recently added to or reduced their stakes in the stock. MetLife Investment Management LLC increased its holdings in Gilead Sciences by 1.9% in the 4th quarter. MetLife Investment Management LLC now owns 329,898 shares of the biopharmaceutical company's stock valued at $30,473,000 after purchasing an additional 6,109 shares during the last quarter. Norinchukin Bank The grew its position in Gilead Sciences by 9.2% in the 4th quarter. Norinchukin Bank The now owns 68,098 shares of the biopharmaceutical company's stock valued at $6,290,000 after acquiring an additional 5,726 shares in the last quarter. Ossiam lifted its position in shares of Gilead Sciences by 3.2% during the fourth quarter. Ossiam now owns 31,975 shares of the biopharmaceutical company's stock worth $2,954,000 after purchasing an additional 1,006 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S boosted its stake in shares of Gilead Sciences by 217.3% in the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 466,506 shares of the biopharmaceutical company's stock valued at $43,091,000 after purchasing an additional 319,498 shares during the period. Finally, Capital International Inc. CA grew its holdings in shares of Gilead Sciences by 23.8% in the fourth quarter. Capital International Inc. CA now owns 312,209 shares of the biopharmaceutical company's stock valued at $28,839,000 after purchasing an additional 60,035 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Gilead Sciences
In related news, CFO Andrew D. Dickinson sold 137,676 shares of the business's stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $102.22, for a total value of $14,073,240.72. Following the sale, the chief financial officer now owns 171,223 shares of the company's stock, valued at $17,502,415.06. The trade was a 44.57 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders sold 302,785 shares of company stock valued at $30,540,875. Company insiders own 0.27% of the company's stock.
Gilead Sciences Stock Up 0.9 %
Shares of Gilead Sciences stock traded up $0.92 during midday trading on Wednesday, hitting $106.43. The company's stock had a trading volume of 8,176,509 shares, compared to its average volume of 7,523,474. The firm has a market capitalization of $132.52 billion, a P/E ratio of 287.64, a PEG ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The stock has a 50-day simple moving average of $109.17 and a 200-day simple moving average of $97.82.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Increases Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were paid a $0.79 dividend. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date was Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.97%. Gilead Sciences's dividend payout ratio is currently 854.05%.
Wall Street Analysts Forecast Growth
GILD has been the subject of several recent research reports. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Morgan Stanley increased their price objective on shares of Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a research report on Tuesday, March 11th. DZ Bank raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a report on Thursday, February 13th. Royal Bank of Canada upped their price objective on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research report on Wednesday, February 12th. Finally, BMO Capital Markets raised their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a report on Wednesday, February 12th. Ten research analysts have rated the stock with a hold rating, sixteen have given a buy rating and four have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $106.92.
Read Our Latest Research Report on GILD
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
